tldrdaily.news logo
Tag

Ginkgo Bioworks

All articles tagged with #ginkgo bioworks

finance1 year ago

"5 Explosive Growth Stocks Set to Soar in 2022"

Wall Street analysts are optimistic about the potential for Ginkgo Bioworks and Intellia Therapeutics, with consensus price targets suggesting significant gains of 144% and 202% respectively over the next 12 months. Ginkgo Bioworks, a synthetic biology company, has faced financial challenges despite its innovative work, while Intellia Therapeutics is developing CRISPR-based gene therapies with promising clinical trial data but faces a long road to commercialization.

via The Motley Fool|
#crispr-based-gene-therapies#finance#ginkgo-bioworks
biopharma2 years ago

Ginkgo and Boehringer Ingelheim join forces for microbial molecule discovery.

Ginkgo Bioworks has partnered with Boehringer Ingelheim in a deal worth up to $406m, using its microbe-based database to find new molecules that the German pharma company could turn into new drugs. The deal includes upfront research and development fees, as well as payments based on hitting R&D, regulatory and commercial markers, and royalties on sales.

via Endpoints News|
#biopharma#biopharma-partnership#boehringer-ingelheim
healthcare2 years ago

Ginkgo Bioworks and Boehringer Ingelheim team up for innovative treatments.

Ginkgo Bioworks has partnered with Boehringer Ingelheim to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery. The two companies will leverage Ginkgo's natural product discovery capabilities to mine Ginkgo's metagenomic sequence database, potentially enabling the rapid identification of lead molecules as starting points for the potential discovery of novel treatments to transform patients' lives.

via PR Newswire|
#boehringer-ingelheim#drug-discovery#ginkgo-bioworks
healthcare2 years ago

Ginkgo Bioworks expands gene therapy capabilities through strategic acquisitions and partnerships.

Ginkgo Bioworks has acquired StrideBio's adeno-associated virus (AAV) capsid assets, which are in the discovery or preclinical stage and focused on cardiovascular diseases. Sanofi has broken ground on a new formulation and filling facility at its site in Swiftwater, PA, which will be a two-story building that will fill both syringes and vials. Amgen's Prolia/Xgeva (denosumab) has shown promise in a small NIH-funded Phase II study for a rare bone disease. The FDA has released its fourth (of four) patient-focused drug development guidance documents, with this latest draft featuring advice on how to collect and submit data on the individual experiences of patients to inform regulatory decisions. PureTech has expressed interest in buying back its weight loss pill spinout Gelesis after a lackluster SPAC.

via Endpoints News|
#amgen#fda#gene-therapy
business2 years ago

Ginkgo Bioworks Forms Strategic Partnerships for Biotechnology Innovation.

Ginkgo Bioworks has sold a lab it acquired through last year's $300m acquisition of Zymergen to Solvay, a multinational chemical and materials company, as part of a strategic collaboration. The companies will partner on manufacturing sustainable materials, including biopolymers with non-medical uses, in a multi-year deal. The financial details of the deal were not disclosed, but Ginkgo said that Solvay paid an undisclosed amount to Zymergen for the building.

via Endpoints News|
#business#collaboration#ginkgo-bioworks